Edesa Biotech, Inc. (NASDAQ:EDSA) is developing EB05 (paridiprubart) as a treatment for acute respiratory distress syndrome (ARDS). The drug is currently being evaluated in a Phase 3 clinical ...

LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today ...

I would like your opinion on the role of corticosteroids in early and late ARDS. When should I institute steroids in my patient with ARDS? The complexities of the ARDSnet study and the variation ...

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) shares are gaining after announcing positive European Medicines Agency feedback on its proposed single confirmatory Phase 3 study of investigational ...

Inhaled sedation with sevoflurane in patients with moderate to severe acute respiratory distress syndrome (ARDS) resulted in fewer ventilator-free days at 28 days and lower 90-day survival than ...

New cell therapy shows promise with ARDS patients Initial trial suggests invariant natural killer cell therapy improves survival Date: February 6, 2024 Source: Anglia Ruskin University Summary: An ...

Opens in a new tab or window HONOLULU -- As suspected, patients with acute respiratory distress syndrome (ARDS) had particularly bad outcomes if they had coexisting pulmonary hypertension (PH), an ...